Skip to main content
Fig. 1 | Journal of Translational Medicine

Fig. 1

From: Incidence and severity of immune-related hepatitis after dual checkpoint therapy is linked to younger age independent of herpes virus immunity

Fig. 1

Incidence of immune-related adverse events (irAE) in the first 100 days after initiation of therapy. A Pie chart depicting the percentage of patients who developed single or multiple types of irAE in the first 100d after therapy initiation. B Bar plot depicting the percentage of patients who developed certain types of adverse events as indicated. C Pie chart depicting the percentage of patients who escaped hepatitis or developed hepatitis of indicated severity in the first 100 days post therapy

Back to article page